{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["21(6)"],"submitter":["Koehler P"],"pubmed_abstract":["Severe acute respiratory syndrome coronavirus 2 causes direct damage to the airway epithelium, enabling aspergillus invasion. Reports of COVID-19-associated pulmonary aspergillosis have raised concerns about it worsening the disease course of COVID-19 and increasing mortality. Additionally, the first cases of COVID-19-associated pulmonary aspergillosis caused by azole-resistant aspergillus have been reported. This article constitutes a consensus statement on defining and managing COVID-19-associated pulmonary aspergillosis, prepared by experts and endorsed by medical mycology societies. COVID-19-associated pulmonary aspergillosis is proposed to be defined as possible, probable, or proven on the basis of sample validity and thus diagnostic certainty. Recommended first-line therapy is either"],"journal":["The Lancet. Infectious diseases"],"pagination":["e149-e162"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7833078"],"repository":["biostudies-literature"],"pubmed_title":["Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance."],"pmcid":["PMC7833078"],"pubmed_authors":["Infectious Diseases Working Party of the German Society for Haematology and Medical Oncology","Lass-Florl C","Gangneux JP","Chakrabarti A","ISHAM Pan Africa Mycology Working Group","International Society for Human Animal Mycology","Hoenigl M","Klimko N","Bruggemann R","Chen SCA","Cornely OA","Infectious Disease Canada","Medical Mycology Society of Nigeria","Oladele RO","Zhu LP","Koehler P","Patterson TF","INFOCUS LATAM/ISHAM Working Group","Boll B","Medical Mycology Society of China Medicine Education Association","Association of Medical Microbiology","Persigehl T","Verweij PE","Interregional Association of Clinical Microbiology and Antimicrobial Chemotherapy","Perfect JR","Asia Fungal Working Group","Colombo AL","Meis JF","Vinh DC","Bassetti M","Ostrosky-Zeichner L","European Society for Clinical Microbiology","European Confederation of Medical Mycology","Infectious Diseases Fungal Infection Study Group","ESCMID Study Group for Infections in Critically Ill Patients","White PL"],"additional_accession":[]},"is_claimable":false,"name":"Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance.","description":"Severe acute respiratory syndrome coronavirus 2 causes direct damage to the airway epithelium, enabling aspergillus invasion. Reports of COVID-19-associated pulmonary aspergillosis have raised concerns about it worsening the disease course of COVID-19 and increasing mortality. Additionally, the first cases of COVID-19-associated pulmonary aspergillosis caused by azole-resistant aspergillus have been reported. This article constitutes a consensus statement on defining and managing COVID-19-associated pulmonary aspergillosis, prepared by experts and endorsed by medical mycology societies. COVID-19-associated pulmonary aspergillosis is proposed to be defined as possible, probable, or proven on the basis of sample validity and thus diagnostic certainty. Recommended first-line therapy is either","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Jun","modification":"2025-04-05T00:14:25.788Z","creation":"2021-02-21T02:31:27Z"},"accession":"S-EPMC7833078","cross_references":{"pubmed":["33333012"],"doi":["10.1016/S1473-3099(20)30847-1"]}}